Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Arjo, Audiocast, Q1'26

By Inderes4/22/2026, 6:00 AM
Arjo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Andréas Elgaard
00:00 - 06:06

Thanks a lot and thanks, everybody for dialing in and listening to Arjo first quarter of 2026. So we believe we have been able to pull together a stable first quarter, and we're happy to share that with you. And also we'll talk a little bit on how we are progressing the work with shaping the future. Arjo. So just to begin a little bit from my side and to remind everybody of who we are and what we do, because we are really very purpose led in everything we do. This is something that is very strong in Arjo. We exist and are present at people's most vulnerable moments. And we help them to keep their integrity and dignity, and really make sure that they have the best possible situation when they need it the most. We, as you know, we work across several product segments and categories. So from patient handling and hygiene to medical beds, the mattresses that go on top often focused on helping to relieve pressure injuries. We work with VTE prevention, diagnostics and disinfection. So these are our product categories. We have about 7,000 people and an annual turnover of approximately 11 billion. And we are truly a global company with sales to more than 100 countries. Let me start with a flyover summary of the first quarter of 2026. So we deliver solid organic net sales growth of 3.8% in Q1, which is within our guidance. And it's really driven this year by a positive trend in US capital sales and strong sales in Rest of the World. And also this year, as you saw in Q4, the flu season was not as strong as it usually is for us in the US, and that has continued. This is despite a somewhat weak flu season. So we think this is really a stable result that we deliver. The gross margin is slightly below last year. And we are of course put under continued pressure when it comes to currency and the tariffs in the US. We are working with trying to compensate this through efficiencies and also to manage our costs in a good way. And then looking into price adjustments, especially considering the situation in West Asia. Still uncertain how this will affect us, but we are preparing for making sure that we manage those effects. To also highlight, we had healthy cash flow in the quarter compared to last year. It's an improvement and it follows the seasonal pattern. So this is also something to note. To mention, the adjusted EBITDA came in at 456 million. One thing to highlight is that we started in the quarter to work on our future strategy. And we have had very intense work and a lot of engagement across the company, and we are progressing in a really good way. And I will come back to this a little bit more towards the end. So if I zoom in a little bit on sales in North America, we had both in Canada and the US, really strong end to the quarter. So month of March was really strong. But in total, I would say that the US continued to grow in the quarter and Canada came in slightly below last year. But they really had met some very strong comparable numbers. So all in all, really strong performance is what we have seen. They were meeting very strong comparable numbers. Of course, when you meet stronger numbers, the percentage growth is affected. And as I mentioned before, for us, the flu season was not as strong as it usually is, but we compensated that through capital sales in patient handling. If you look at the rest of our sales beyond North America, in Western Europe, we were struggling a little bit, and it's mainly the UK that is causing the decline. But that stands for the decline. And most other markets are performing in a good way. And especially France and Italy have had really good performance in the quarter. The rest of the world beyond Europe and North America was really, really strong. And the growth was really driven by strong performance in several markets. But a shout out, especially to South Africa, that delivered a large medical beds order in their region. And I just want to hang on that topic just because it gives some flavor to what we're doing. So we have modernized 36 healthcare facilities in South Africa. This was a special product tailored for their needs. So more than 2,300 new beds and mattresses were installed. And this was not just a logistic exercise. It's an installation exercise. It needs to be done when it suits the hospital and it needs to be done with a good margin and good cash conversion. And all of this came to life through really good, strong teamwork from customer to the supply chain. So by that, I hand over to Christofer.

Christofer Carlsson
06:08 - 11:08

Thank you Andreas. And as Andreas stated, we had a stable start of the year. Overall, our gross margin came in at 42.6% compared to last year's 43.7%. Looking at the drivers, the growth in patient handling improved group margins, driven by strong development for our floor lift, MaxiMove, and ceiling. Our diagnostic business also improved margins, driven by higher volumes and an unfavorable sales mix. The rental business gross margin slightly increased, driven by France, UK and Australia, while the US had a negative development due to weaker flu season and some capital conversion among customers. However, the main part of the gap came from an unfavorable product and country mix, impacting the gross margin by minus one percentage point, mainly related to the large medical bed order in South Africa. At the same time, U.S. U.S. tariffs had a negative impact of 10 million year over year, representing a 0.4 percentage point decline in gross margin. In addition, FX had a minor negative impact on gross margin, but in absolute numbers, gross profit was negatively affected. The negative effects amounted to 123 million SEK. Finally, our service business margins were in line with last year when excluding U.S. Tariffs. If we now move on to the EBIT slide. Next slide please. As you can see, adjusted EBIT in Q1 came in at 190 million compared to 208 million last year. However, when excludingU.S. Tariff and FX, the result is in line with last year. Looking at the costs, OpEx declined in the quarter due to FX effects. At the same time, the organic OpEx increase was 2.8%. In addition, we had a positive effect from revaluation of accounts receivable and accounts payable of 3 million SEK in the quarter reported under other income and expenses. Last year, the equivalent amount was -34 million SEK, resulting in a delta of plus 37 million. Year over year. So overall, the total FX impact on Adjusted EBIT amounts therefore to a minor amount of -7 million SEK in the quarter. Moving to EBITDA, adjusted EBITDA for the quarter was 456 million, compared to 486 million last year, and adjusted EBITDA margin was in line with last year and came in at 16.9% versus 17.7% last year. The EBIT margin increased to 6.8% versus 5.9% last year. This improvement was supported by lower restructuring costs that came in at -6 million SEK in the quarter versus 40 million SEK last year. Now we move over to working capital and cash flow. Next slide please. Operating cash flow improved in the quarter amounting to 237 million SEK. This was 53 million SEK higher year over year, mainly due to improved cash flow from working capital following a normal seasonal pattern. The change in working capital was -142 million SEK versus -180. Working capital days increased to 83, up from 81 in Q1. Cash conversion in the quarter improved to 52.7%, compared to 41.3% last year. For reference, our cash flow from investing activities was -135 million SEK, compared to -215 in Q1 2025. The decrease is mainly due to 48 million lower investment in rental assets. Let's now turn to the net debt and leverage. Next slide please. The decrease in net debt this quarter is driven by improved operating cash flow, lower investments, and positive effects. Our financial net came in at -36 million compared to -43 in Q1 25. The improvement relates to some positive effects. Our cash position remains strong. Net debt to adjusted EBITDA stayed flat versus year end and came in at 2.2. Our equity ratio stood at 50.5%, up from 49.8% at year-end 2025, mainly due to positive effects in equity. With that, I will now hand it back to you, Andreas.

Andréas Elgaard
11:08 - 14:06

Thank you so far. So I thought that it would be good, maybe to just share a little bit on how the work of shaping the future of Arjo is going. And it's too early to reveal anything, but I can still try to give you a flavor on what we're doing. And we put the headline here that it will be a story of untapped potential because, being new to Arjo and soon four months into the role, I see a lot of potential in the people, in our relationships with our suppliers, and with our customers. It's really, it's not just an industry that has healthy growth expectations, but Arjo as an organization is really filled with potential. But this is, in order to be able to untap that, we really need to have clarity on where we're going and make sure that we build the capability to execute as well. So, in one way of doing that is by inviting leaders from across the organization to make sure that we build common ground and create alignment. We create understanding on where we are and where we need to be in the future. And by doing that, you don't just get a strategy that comes from the top. You get a strategy that is well anchored across the organization, and that really helps you when it's time for execution. So our ambition is to go from strategizing straight into execution. That is the ambition, and creating clarity in where we're going is really important for everything from product development to supplier relationship development. But it's also very important if we want to continue to grow also in new product segments, or if we want to open new segments where care is moving. It will also be something that will guide us if we need to accelerate our growth or our strategic movement through acquisitions in the future. But strategy and talking too much about the future sometimes can dilute the focus on here and now. And I, for one, am super focused on that. We need to deliver two things. We need to deliver clarity for the future so we know how to execute and build the future. Arjo. But we also need to deliver results short term. So what you can expect from us is a strategy that will focus both on here and now, and how we lay the foundation for the future. So you will have both. And our ambition is to get this strategy approved during summer and that we will be able to communicate that to you after the summer. That means the second half of 2026. So that's a little bit the status on where we are in the work of creating the future. Arjo. And by that, we hand over to the Q&A section.

Operator
14:07 - 14:24

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the Q&A. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Wetterqvist from SB1 Markets. Please go ahead.

Philip Wetterqvist
14:26 - 14:50

Good morning. Thank you for taking my questions. I have a couple. First. Can you quantify a little bit more on the contribution from the 36 facilities in South Africa to global sales? Organic growth, like what would the underlying organic rate have been excluding this order? And how does this inform the run rate for Q2? The first one.

Andréas Elgaard
14:52 - 15:27

Okay. Thank you for your question. I don't think we have communicated the size of the single order. And I do think that when we have material orders, we will issue a press release and specify those things. So we have not done that. So we are not giving guidance on that because that would reveal information to competitors that we don't want to reveal, but you know, 2300. That refers to more than 2,300 beds to 36 care facilities. It is. It is a substantial order, but we don't judge it being material.

Philip Wetterqvist
15:29 - 15:48

Okay. Thank you. And my second question. You mentioned the Middle East cost pressure from energy and transportation as a fresh headwind here in the report. Did you see any impact already here in Q1 or do you anticipate it in Q2? And what is the current run rate assumption for 2026?

Andréas Elgaard
15:49 - 17:11

Yeah. Thanks for the question. So we have seen the minor effects in Q1, but of course, we and everybody else in the world are very much aware of how much oil affects not just the energy sector, but every, I would say every process industry and every food production, you know, farm, in the world. Through the production of fertilizers. So of course, this will have effects, but we are mindful. So we are preparing to try to mitigate that in the ways that we can. We don't give forecasts on what that might be because, and I don't think Arjo is the best equipped to give forecasts on the financial consequences of the crisis. That is ongoing right now. But given that, of course, we are preparing ourselves for the scenarios that we see internally. So I hope that answers your question enough. If this conflict becomes short-term, hopefully there will still be effects, that's for sure. But if it becomes short term, I also think it will be something that the world will be able to manage. And this is something that affects Arjo in the same way as it affects everybody else.

Philip Wetterqvist
17:13 - 17:16

All right. Thank you. Those were all my questions for now, I'll jump back into the queue. Q&A.

Operator
17:19 - 17:37

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Andréas Elgaard
17:40 - 18:17

Okay, thank you very much. So today is the Annual General Meeting. So we are super excited. There will be more than 120 shareholders that will come and listen to us, and we will give a similar message to them. But of course, we will focus on 2025. We'll give a short highlight of the first quarter this year. And we will also give some flavor on the strategy work. So we'll share a movie where different leaders from Arjo are talking about that. So we are really excited about that. And by that, we say thank you for this call and we remain at your disposal. Bye bye.

Christofer Carlsson
18:18 - 18:20

Bye bye. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…